Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Amba Auto Sales IPO Review: Apply or Avoid?

The moment you hear the names of Bajaj Auto and LG Electronics, you know investors are going to trust this company with their investment.

We are talking about Amba Auto Sales and Services, an authorized dealer of Bajaj Auto, and LG Electronics, which is launching its NSE SME IPO.

The IPO will be open for subscription on April 27, 2026, and close on April 29, 2026. The Amba Auto Sales and Services IPO price band is set between ₹130 to ₹135 per share. As per the RHP, the company plans to raise around ₹65 crores through an Initial public offering (IPO).
Amba Auto Sales IPO

As an investor, it can be very challenging to decide whether the Amba Auto Sales and Services IPO is a good or bad investment. Not anymore, as in this blog, we will provide you with all the necessary details related to the Amba Auto Sales and Services IPO to help you decide whether you should apply or not. Read on to know the IPO risks, strengths, valuation, financial details, and expert opinion to make your investment decision better. 

Amba Auto Sales and Services IPO Review 

ReviewerRecommendation
IPO WatchNeutral

Strengths:

  • The firm is backed by experienced promoters and a management team, maintaining a long-term relationship with clients and dealers. 
  • Supported by a strong presence in Bengaluru, an efficient showroom network, optimized inventory management, and warehousing facilities. 
  • Offering a wide range of products and services across multiple segments, including electric vehicles (EVs), sports bikes, motorcycles, auto rickshaws, and the Qute quadricycle. 
  • Established long-term relationships with its Major OEMs, Bajaj Auto for vehicles and LG Electronics for electronic appliances. 
  • Over 3 years, the company has maintained a good Return on Equity of 52.2%.

Weaknesses: 

  • The company’s success and dependency are on its OEMs in India. Any harm to its OEM’s reputation or failure to stay competitive could negatively impact its business and financial performance.
  • As of March 2025, the firm’s debt-to-equity ratio stands at 3.65, and total borrowings of ₹57.42 crore, if not managed, can increase financial risk and growth.
  • As of 2025, the company has reported a negative cash flow of ₹692.60 lakhs. If continued in the future can affect the operations and the company’s growth.
  • Being in the automobile industry exposes them to new economic conditions and various other factors. Any decline in the demand for the products, parts, or accessories can adversely affect the business and its operations. 

Promoters & Track Records, if any 

  • Mr Pradeep Kumar Lohia, aged about 76 years, is the Promoter and Director of our Company. He holds 44,96,400 of Equity shares, representing 33.31% of Pre-Offer equity capital.
  • Mr Rakesh Kumar Lohia, aged about 51 years, is the Promoter and Director of our Company. He holds 44,96,400 of Equity shares, representing 33.31% of Pre-Offer equity capital.
  • Mr Vikash Kumar Lohia, aged about 45 years, is the Promoter and Director of our Company. He holds 40,50,000 of Equity shares, representing 30.00% of pre-Offer equity capital.

Peer Comparison with the Company

Name of the CompanyFace Value(₹)Basic EPS (₹) Diluted EPS(₹) RONW (%)P/E RatioNAV(₹) 
Amba Auto Sales and Services Service 105.76  5.76  69.09% 23.43x11.22 
Popular Vehicles and Services Limited 2(1.47)  (1.47) -1.61 % NA89.72 
Bikewo Green Tech Limited 100.59 0.59 2.38% 30.68x 29.55  
Resourceful Automobile Limited 105.65 5.65 12.41%6.90x63.40 

Industry Peer Group P/E ratio 

The peer group P/E ratio ranges from 11.59 (Resourceful Automobile Limited) to 27.12 (ikeWo Green Tech Limited), with an industry average of 19.35.

Expansion 

  • The proceeds of ₹6.32 crore will be used for setting up new showrooms and renovating existing ones 
  • A fund of ₹43 crore will be utilized towards working capital requirements.
  • Lastly, the remaining funds will be utilized towards general corporate purposes.

Amba Auto Sales and Services IPO — Should You Apply or Not?

On one side, the automobile business, and on the other, electronic appliances, Amba Auto Sales and Services started its business in 2005. It provides sales, services, and handles dealership operations. The company’s products are divided into 2 parts: the Automobile Segment and the Electronic Segment. It is a low-margin and high-volume business. 

With a strong presence in Bangalore, with 254 employees, the firm is gradually expanding. The company’s growth is strong, but it cannot ignore the debt of 3.54. Net worth and reserves are strong, but its borrowings are double. Financially, the revenue and net profit are growing 30% YOY, outperforming its competitors. 

The company is valued at a P/E of 23x, on the upper price band. Compared to the industry P/E, the IPO seems to be highly valued or priced aggressively. As of 25th April, the GMP of the Amba Auto Sales IPO is ₹0. 

My verdict: The firm operates in a highly competitive sector, which can impact its margins. High-risk investors can apply for this IPO with a medium to long-term perspective. Cautious investors wants short-term gains should only apply for this IPO after evaluating GMP, subscription numbers and in-depth research.

Please note: 

Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team. 

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi

Leave a Reply

Your email address will not be published. Required fields are marked *